Interact with experts and peers.

Recent Posts

10 of 82 Shown
  • My Approach to First-line ART for Patients With High Cardiovascular Disease Risk

    William G. Powderly MD - 10/6/2015
    When treating HIV in patients with risk factors for CVD, selecting the optimal ART regimen is only part of the equation.
  • Clinical Case: Estimating Cardiovascular Disease Risk With the ASCVD Event Calculator

    David A. Wohl MD - 9/16/2015 1 comment / Last Comment: 9/17/2015
    How I used the ASCVD event calculator to estimate CVD risk for an HIV-infected patient with stably suppressed HIV-1 RNA.
  • How I Approach Patients Who Are Reluctant to Initiate ART

    Daniel R. Kuritzkes MD - 9/8/2015 1 comment / Last Comment: 9/10/2015
    In this patient case example, I review how I counsel patients who are hesitant to begin first-line ART.
  • Management of HCV/HIV Coinfection: New Data From IAS 2015

    Jürgen K. Rockstroh MD - 9/8/2015 1 comment / Last Comment: 9/10/2015
    My summary of new and noteworthy data on managing HCV/HIV coinfection from IAS 2015.
  • Adherence Concerns: Are We Limited to Boosted PIs?

    Joseph J. Eron, Jr. MD - 8/24/2015 3 comments / Last Comment: 9/3/2015
    My take on why an integrase inhibitor–based regimen makes sense for an ART-naive patient who struggles with adherence to care and medications.
  • IAS 2015: A Preview of Key Data to Be Presented in Vancouver

    Chris Beyrer MD, MPH - 7/17/2015 6 comments / Last Comment: 8/3/2015
    Here is my take on the most anticipated studies that will be presented in Vancouver this year.
  • My Approach to Selecting First-line ART for a Patient With Many Options

    David A. Cooper MD, DSc - 7/10/2015 6 comments / Last Comment: 7/27/2015
    David A. Cooper, MD, DSc, introduces his strategies for selecting therapy based on a recent patient case. At an upcoming symposium in Vancouver, Dr. Cooper and his colleagues will discuss their approach to treatment choice in a range of patient scenarios.
  • How I Select Among Integrase Inhibitors for Treatment-Naive Patients in 2015

    Paul E. Sax MD - 7/7/2015 7 comments / Last Comment: 9/3/2015
    Using a recent case example, I describe how I choose among the DHHS-recommended INSTI-based regimens in the first-line setting.
  • Shifting Roles for Single-Tablet Regimens in the Latest DHHS Guidelines

    Karam Mounzer MD - 6/16/2015
    I explain how the concept of “net potency” plays a key role when considering the use of single-tablet regimens as first-line therapy.
  • How I Implement Shared Decision Making When Selecting First-line ART

    Kevin M. O'Hara MMSc, MS, PA-C - 6/12/2015
    I review my patient-centered approach to choosing the right regimen as initial therapy.
10 of 82 Shown
Show 10 More